Pilar Alonso, MD
Infectious Disease · Wareham, MANPI 1841295748
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,870 of the $30,888 with a category attached, or 83.8%. Gilead accounts for 96.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $11,791 and has fallen 98.7% since, to $148 in 2025. Among infectious disease clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $401.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$30K
- Johnson & Johnson$211
- Janssen Products, LP$183
- W. L. Gore & Associates, Inc.$148
- Mallinckrodt Enterprises LLC$122
- Hologic Sales And Service, LLC$120
- plus $400 from 8 others
What the payments were for
- Speaking & faculty fees$25,87084%
- Travel & lodging$2,6309%
- Food & beverage$2,2607%
- Education$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 42 | $29,704 |
| Johnson & Johnson(2 entities) | 7 | $211 |
| Janssen Products, LP | 2 | $183 |
| W. L. Gore & Associates, Inc. | 1 | $148 |
| Mallinckrodt Enterprises LLC | 1 | $122 |
| Hologic Sales And Service, LLC | 1 | $120 |
| Merck | 7 | $101 |
| Napo Pharmaceuticals Inc | 5 | $76 |
| AbbVie | 3 | $61 |
| Viiv Healthcare Company | 3 | $56 |
| Scilex Pharmaceuticals Inc. | 1 | $44 |
| Insmed, Inc. | 2 | $29 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Indivior Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$13,645
- GORE EXCLUDER AAA Endoprosthesis$148
- OFIRMEV$122
- Cervical Cancer Screening$120
How this compares
$30,888 in reported general payments places this provider in the 90th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 22 | $98 |
| Doxycycline Hyclate | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Wareham
- Yoav GolanBoston$1.1M
- Claudia MartorellSpringfield$990K
- Nesli BasgozBoston$901K
- Todd EllerinBoston$843K
- Peter SebenyNewburyport$343K
- Paul SaxBoston$320K
- Davidson HamerBoston$221K
- Camille KottonBoston$195K
- David SnydmanBoston$141K
- Eric RosenbergBoston$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.